{"id":75197,"date":"2026-08-18T12:03:53","date_gmt":"2026-08-18T04:03:53","guid":{"rendered":"https:\/\/flcube.com\/?p=75197"},"modified":"2026-08-18T12:03:54","modified_gmt":"2026-08-18T04:03:54","slug":"enginprime-medical-closes-nearly-100-million-rmb-series-a-round-with-qiming-venture-partners-as-sole-investor-capital-earmarked-for-opusone-pvad-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75197","title":{"rendered":"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Enginprime Medical<\/strong> announced the completion of its <strong>Series A funding round of nearly 100 million RMB<\/strong>, with <strong>Qiming Venture Partners<\/strong> participating as the <strong>sole investor<\/strong>. Proceeds will be directed primarily toward registration clinical trials for the company&#8217;s core product, <strong>OpusOne<\/strong>, in China, alongside overseas early\u2011stage clinical development.<\/p>\n\n\n\n<h2 id=\"h-funding-milestone\" class=\"wp-block-heading\">Funding Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Round<\/strong><\/td><td>Series A<\/td><\/tr><tr><td><strong>Size<\/strong><\/td><td>~100 million RMB<\/td><\/tr><tr><td><strong>Investor<\/strong><\/td><td>Qiming Venture Partners (sole)<\/td><\/tr><tr><td><strong>Core Product<\/strong><\/td><td>OpusOne (percutaneous ventricular assist device)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>18 Aug 2026<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Domestic registration trials for OpusOne; overseas early\u2011stage trial filings and execution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-company-amp-product-profile\" class=\"wp-block-heading\">Company &amp; Product Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2023; high\u2011tech enterprise focused on R&amp;D and commercial translation of innovative cardiovascular medical technologies.<\/li>\n\n\n\n<li><strong>Focus Area:<\/strong> Percutaneous ventricular assist device (<strong>pVAD<\/strong>) sector \u2014 minimally invasive mechanical circulatory support for acute heart failure.<\/li>\n\n\n\n<li><strong>Flagship Product:<\/strong> <strong>OpusOne<\/strong>, a next\u2011generation ventricular assist system.<\/li>\n\n\n\n<li><strong>Design Philosophy:<\/strong> Small\u2011footprint, high\u2011flow architecture aimed at improving portability and clinical usability in critical care settings.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-use-of-proceeds-amp-development-roadmap\" class=\"wp-block-heading\">Use of Proceeds &amp; Development Roadmap<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Domestic:<\/strong> Accelerate registration clinical trials for <strong>OpusOne<\/strong> in China, a key step toward NMPA regulatory approval.<\/li>\n\n\n\n<li><strong>International:<\/strong> Fully support the filing and execution of early\u2011stage clinical trials overseas, signaling a global development pathway from an early stage.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiovascular Device Landscape:<\/strong> China&#8217;s aging population and rising incidence of heart failure are expanding demand for advanced mechanical circulatory support, making pVAD a high\u2011growth device category.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Enginprime&#8217;s emphasis on compact, high\u2011flow systems targets an unmet need for portable, catheter\u2011based cardiac support in intensive care workflows.<\/li>\n\n\n\n<li><strong>Investor Signal:<\/strong> Qiming Venture Partners&#8217; sole participation underscores continued institutional appetite for differentiated cardiovascular medtech in China.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> With Series A capital secured, Enginprime is positioned to advance OpusOne through pivotal clinical and regulatory milestones in both domestic and international markets.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial timelines, regulatory filings, and commercialization expectations for OpusOne. Actual results may differ due to risks including trial outcomes, regulatory review, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Enginprime Medical announced the completion of its Series A funding round of nearly 100 million&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[69,4901,20],"class_list":["post-75197","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cvd","tag-enginprime-medical","tag-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Enginprime Medical announced the completion of its Series A funding round of nearly 100 million RMB, with Qiming Venture Partners participating as the sole investor. Proceeds will be directed primarily toward registration clinical trials for the company&#039;s core product, OpusOne, in China, alongside overseas early\u2011stage clinical development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75197\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Enginprime Medical announced the completion of its Series A funding round of nearly 100 million RMB, with Qiming Venture Partners participating as the sole investor. Proceeds will be directed primarily toward registration clinical trials for the company&#039;s core product, OpusOne, in China, alongside overseas early\u2011stage clinical development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75197\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-18T04:03:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-18T04:03:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75197#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75197\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials\",\"datePublished\":\"2026-08-18T04:03:53+00:00\",\"dateModified\":\"2026-08-18T04:03:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75197\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CVD\",\"Enginprime Medical\",\"Finance\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75197#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75197\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75197\",\"name\":\"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-18T04:03:53+00:00\",\"dateModified\":\"2026-08-18T04:03:54+00:00\",\"description\":\"Enginprime Medical announced the completion of its Series A funding round of nearly 100 million RMB, with Qiming Venture Partners participating as the sole investor. Proceeds will be directed primarily toward registration clinical trials for the company's core product, OpusOne, in China, alongside overseas early\u2011stage clinical development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75197#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75197\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75197#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Enginprime Medical announced the completion of its Series A funding round of nearly 100 million RMB, with Qiming Venture Partners participating as the sole investor. Proceeds will be directed primarily toward registration clinical trials for the company's core product, OpusOne, in China, alongside overseas early\u2011stage clinical development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75197","og_locale":"en_US","og_type":"article","og_title":"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials","og_description":"Enginprime Medical announced the completion of its Series A funding round of nearly 100 million RMB, with Qiming Venture Partners participating as the sole investor. Proceeds will be directed primarily toward registration clinical trials for the company's core product, OpusOne, in China, alongside overseas early\u2011stage clinical development.","og_url":"https:\/\/flcube.com\/?p=75197","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-18T04:03:53+00:00","article_modified_time":"2026-08-18T04:03:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75197#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75197"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials","datePublished":"2026-08-18T04:03:53+00:00","dateModified":"2026-08-18T04:03:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75197"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CVD","Enginprime Medical","Finance"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75197#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75197","url":"https:\/\/flcube.com\/?p=75197","name":"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-18T04:03:53+00:00","dateModified":"2026-08-18T04:03:54+00:00","description":"Enginprime Medical announced the completion of its Series A funding round of nearly 100 million RMB, with Qiming Venture Partners participating as the sole investor. Proceeds will be directed primarily toward registration clinical trials for the company's core product, OpusOne, in China, alongside overseas early\u2011stage clinical development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75197#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75197"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75197#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor \u2013 Capital Earmarked for OpusOne pVAD Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75197"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75197\/revisions"}],"predecessor-version":[{"id":75200,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75197\/revisions\/75200"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}